보고서 요약(국문)

보고서 개요
글로벌 암 종양 프로파일링 시장은 2023년 95억 달러 규모에 도달했으며, 2024년부터 2031년까지 연평균 9.4% 성장하여 2031년에는 191억 5천만 달러에 이를 것으로 예상됩니다.
종양 프로파일링은 종양 생물학을 구성하고 암 성장의 근본 원인이 되는 유전자 돌연변이 또는 기타 변형을 확인하는 실험실 검사입니다. 이 정보는 의사가 종양 프로파일을 기반으로 개인 맞춤형 치료 계획을 수립하는 데 도움이 될 수 있습니다. 종양 프로파일링은 종양 전문의가 환자의 종양 경로가 사용 가능한 표적 치료법과 일치하는지 판단하는 데 사용하는 기술입니다. 종양 프로파일링을 통해 암 진행 및 치료 저항성의 원인이 되는 종양의 분자적 특성을 심층적으로 분석할 수 있습니다.
종양 프로파일링(바이오마커 검사라고도 함)은 암세포에 대한 상세하고 민감한 실험실 분석입니다. 이 검사의 목적은 특정 바이오마커 돌연변이를 밝히고 발견된 돌연변이에 맞는 표적 치료법을 식별하는 것입니다. 종양 프로파일링은 가장 효과적인 치료 계획을 수립하고 안내하는 데 도움이 될 수 있습니다. 종양 프로파일링은 종양 조직 샘플을 채취하는 것으로 시작됩니다. 조직은 일반적으로 코어 생검을 통해 채취됩니다.
시장 동향: 성장 동력
암 발병률 증가
전 세계 암 종양 프로파일링 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 암 발병률의 증가는 시장 성장을 견인하는 주요 요인입니다. 예를 들어, 미국 국립보건원(NIH)이 2023년 1월에 발표한 자료에 따르면, 미국에서는 1,958,310건의 새로운 암 발병 사례와 609,820명의 암 사망자가 발생할 것으로 예상됩니다. 전립선암 발병률은 20년간의 감소세 이후 2014년부터 2019년까지 매년 3%씩 증가하여 99,000건의 새로운 사례가 추가로 발생했습니다.

또한, wcrf.org에 따르면 비흑색종 피부암(NMSC)을 포함한 2022년 전 세계 암 발생 건수는 19,976,499건이었습니다. NMSC를 제외하면 2022년 전 세계 암 발생 건수는 18,741,966건으로 감소했습니다. 이 중 남성은 9,566,825명, 여성은 9,175,141명이었습니다. 더불어, 국제암연구소(IARC)에 따르면 2022년 한 해 동안 약 2천만 건의 새로운 암 발생 사례(비흑색종 피부암[NMSC] 포함)와 970만 건의 암 사망 사례(NMSC 포함)가 발생했습니다. 이러한 추정치는 남녀를 불문하고 약 5명 중 1명이 평생 동안 암에 걸리고, 남성은 약 9명 중 1명, 여성은 약 12명 중 1명이 암으로 사망한다는 것을 시사합니다. 2022년 폐암은 전 세계적으로 가장 흔하게 진단된 암으로, 약 250만 건의 새로운 사례가 발생하여 전체 암의 8분의 1(전 세계 모든 암의 12.4%)을 차지했습니다.
제한 요인
시술 관련 높은 비용, 의료 인프라 부족, 보험 적용 정책의 부재, 샘플 수집 및 보관 조건의 기술적 문제 등이 시장 성장을 저해할 것으로 예상됩니다.
시장 세분화 분석
전 세계 암 종양 프로파일링 시장은 암 유형, 기술 유형, 바이오마커 유형, 응용 분야, 최종 사용자 및 지역별로 세분화됩니다.
차세대 시퀀싱(NGS) 부문은 전 세계 암 종양 프로파일링 시장 점유율의 약 48.9%를 차지했습니다.
차세대 시퀀싱 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이 부문에서는 기술 발전이 시장 성장을 견인할 것입니다.
차세대 시퀀싱(NGS), 또는 대규모 병렬 시퀀싱이라고도 하는 이 기술은 암에 대한 방대한 양의 유전체 정보를 확보하는 효과적인 방법입니다. 대부분의 NGS 기술은 합성 시퀀싱을 중심으로 이루어집니다. 시퀀싱할 각 DNA 조각은 어레이에 결합되고, DNA 중합효소가 표지된 뉴클레오티드를 순차적으로 추가합니다. 고해상도 카메라가 통합되는 각 뉴클레오티드의 신호를 포착하고 공간 좌표와 시간을 기록합니다. 컴퓨터 프로그램은 각 지점의 시퀀스를 추론하여 연속적인 DNA 시퀀스(리드)를 생성합니다.
예를 들어, 2023년 4월 애질런트 테크놀로지스(Agilent Technologies Inc.)는 다양한 고형암 유형의 체세포 변이 프로파일링을 위해 설계된 애질런트 슈어셀렉트 암 CGP 어세이(Agilent SureSelect Cancer CGP Assay)를 출시했습니다. 이 범암 어세이는 주요 암 데이터베이스에서 선별하고 주요 임상 암 연구자들과 협력하여 구축한 679개 유전자로 구성된 NGS 패널을 기반으로 합니다.
시장 지역 분석
북미는 전 세계 암 종양 프로파일링 시장 점유율의 약 43.6%를 차지했습니다.
북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 지역의 암 발병률 증가와 기술 발전은 시장 성장을 견인하는 요인입니다.
예를 들어, 미국 국립보건원(NIH)이 2024년 1월에 발표한 기사에 따르면, 미국에서는 2,001,140건의 새로운 암 발병 사례와 611,720명의 암 사망자가 발생할 것으로 예상됩니다. 암 사망률은 2021년까지 지속적으로 감소하여 1991년 이후 400만 명 이상의 사망을 예방했습니다. 이는 흡연 감소, 일부 암의 조기 발견, 그리고 보조 요법 및 전이성 암 치료 모두에서 개선된 치료법 덕분입니다. 그러나 이러한 성과는 10대 암 중 6개 암의 발병률 증가로 위협받고 있습니다.

또한, 의사결정 의학 분야의 선두 기업인 Pillar Biosciences, Inc.는 2023년 9월에 액체 생검 기반의 범암 종양 프로파일링 솔루션을 연구실에 제공하도록 설계된 연구용(RUO) 차세대 시퀀싱(NGS) 키트인 oncoReveal Core LBx를 전 세계에 출시한다고 발표했습니다.
시장 세분화
암 유형별
폐암
전립선암
유방암
대장암
흑색종
기타
기술 유형별
면역 분석법
차세대 염기서열 분석법
중합효소 연쇄 반응(PCR)
현장 혼성화(ISH)
마이크로어레이
기타
바이오마커 유형별
유전체 바이오마커
단백질 바이오마커
기타
응용 분야별
연구 응용 분야
임상 응용 분야
진단
맞춤형 의약품
기타
최종 사용자별
병원
진단 센터
연구 및 학술 기관
기타
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽 지역
남미
브라질
아르헨티나
기타 남미 지역 미국
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양 지역
중동 및 아프리카
시장 경쟁 환경
글로벌 암 종양 프로파일링 시장의 주요 글로벌 기업으로는 Qiagen N.V, NeoGenomics Laboratories, Genomic Health Inc., Caris Life Sciences, Helomics Corporation, NanoString Technologies Inc., Sysmex Corporation, Ribomed Biotechnologies Inc., Roche Diagnostics 및 Illumina Inc. 등이 있습니다.
주요 개발 사항
2024년 5월, Foundation Medicine Inc.는 318개 유전자에서 암 관련 융합을 검출하는 조직 기반 RNA 시퀀싱 검사인 FoundationOne®RNA의 미국 출시를 발표했습니다. FoundationOne RNA는 모든 고형암에서 융합 유전자를 보고할 수 있으며, 비소세포폐암(NSCLC), 췌장암, 담관암, 육종, 갑상선암, 방광암과 같은 특정 암에서 융합 유전자를 검출하는 데 유용할 수 있습니다.
2023년 11월, Illumina Inc.는 차세대 분산형 액체 생검 유전체 프로파일링 분석법을 발표했습니다. 새로운 TruSight™ Oncology 500 ctDNA v2(TSO 500 ctDNA v2)는 조직 검사가 불가능하거나 조직 기반 검사를 보완하기 위해 혈액에서 순환 종양 DNA(ctDNA)를 비침습적으로 종합 유전체 프로파일링(CGP)할 수 있는 연구용 분석법입니다.
보고서 구매 이유:
암 유형, 기술 유형, 바이오마커 유형, 응용 분야, 최종 사용자 및 지역별 글로벌 암 종양 프로파일링 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

트렌드 분석 및 공동 개발을 통해 사업 기회를 파악하세요.
전 세계 암 종양 프로파일링 시장의 모든 세그먼트에 대한 다양한 데이터 포인트가 포함된 Excel 데이터 시트가 제공됩니다.
PDF 보고서는 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 결과를 담고 있습니다.
주요 업체들의 핵심 제품을 모두 포함하는 제품 매핑이 Excel 파일로 제공됩니다.
전 세계 암 종양 프로파일링 시장 보고서는 약 51개의 표, 54개의 그림, 181페이지 분량입니다.
대상 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자 은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Cancer Tumor Profiling Market reached US$ 9.5 billion in 2023 and is expected to reach US$ 19.15 billion by 2031, growing at a CAGR of 9.4% during the forecast period 2024-2031.
Tumor profiling is a laboratory test to check for gene mutations or other alterations that make up the tumor biology and underlie the cancer growth. This information can help physicians build a personalized treatment plan based on the tumor profile. Tumor profiling is the technology oncologists use to determine if the pathways of a patient’s tumor match up with available targeted treatments. Tumor profiling allows for deep analysis of a tumor’s molecular characteristics that are responsible for cancer progression and therapy resistance.
Tumor profiling, also known as biomarker testing, is a detailed and sensitive laboratory analysis of cancer cells. The purpose of this testing expose specific biomarker mutations and identify targeted therapies matched to any found mutations. Tumor profiling can help guide and identify the most effective treatment plan. Tumor profiling starts with obtaining a sample of tumor tissue. The tissue is usually collected through a core biopsy.
Market Dynamics: Drivers
Increasing prevalence of cancer
The demand for the global cancer tumor profiling market is driven by multiple factors. The rising prevalence of cancers propels the market growth. For instance, according to an article published by nih.gov in January 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases.
Moreover, according to wcrf.org, including non-melanoma skin cancer (NMSC) there were 19,976,499 cancer cases in 2022. When NMSC was excluded, this number dropped to 18,741,966 cancer cases around the world in 2022. Of these, 9,566,825 were in men and 9,175,141 in women. Moreover, according to IARC, There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers globally).
Restraints
Factors such as high cost associated with the procedure, lack of healthcare infrastructure, lack of reimbursement policies, and technical issues in sample collection and storage conditions are expected to hamper the market.
Market Segment Analysis
The global cancer tumor profiling market is segmented based on cancer type, technology type, biomarker type, application, end-user, and region.
The segment next-generation sequencing accounted for approximately 48.9% of the global cancer tumor profiling market share
The next-generation sequencing segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market.
Next-generation sequencing (NGS), also known as massively parallel sequencing, represents an effective way to capture a large amount of genomic information about a cancer. Most NGS technologies revolve around sequencing by synthesis. Each DNA fragment to be sequenced is bound to an array, and then DNA polymerase adds labeled nucleotides sequentially. A high-resolution camera captures the signal from each nucleotide becoming integrated and notes the spatial coordinates and time. The sequence at each spot can then be inferred by a computer program to generate a contiguous DNA sequence, referred to as a read.
For instance, in April 2023, Agilent Technologies Inc. announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types. The pan-cancer assay design is based on an NGS panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers.
Market Geographical Analysis
North America accounted for approximately 43.6% of the global cancer tumor profiling market share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of cancer, and technological advancements, in this region, help to propel the market.
For instance, according to an article published by nih.gov in January 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers.
Moreover, in September 2023, Pillar Biosciences, Inc., the leader in Decision Medicine, announced the global launch of oncoReveal Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling.
Market Segmentation
By Cancer Type
Lung Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Melanoma cancer
Others
By Technology Type
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
In-Situ Hybridization
Microarray
Others
By Biomarker Type
Genomics Biomarker
Protein Biomarker
Others
By Application
Research Applications
Clinical Applications
Diagnostics
Personalized Medicines
Others
By End-User
Hospitals
Diagnostic Centers
Research and Academic Institutions
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the global cancer tumor profiling market include Qiagen N.V, NeoGenomics Laboratories, Genomic Health Inc., Caris Life Sciences, Helomics Corporation, NanoString Technologies Inc., Sysmex Corporation, Ribomed Biotechnologies Inc., Roche Diagnostics and Illumina Inc. among others.
Key Developments
In May 2024, Foundation Medicine Inc. announced the U.S. launch of FoundationOne®RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes. FoundationOne RNA enables reporting of fusions in all solid tumors and may be valuable for detecting fusions in certain cancers, such as non-small cell lung cancer (NSCLC), pancreatic cancer, cholangiocarcinoma, sarcoma, thyroid cancer, and bladder cancer.
In November 2023, Illumina Inc. announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight™ Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available or to complement tissue-based testing.
Why Purchase the Report?
To visualize the global cancer tumor profiling market segmentation based on cancer type, technology type, biomarker type, application, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global cancer tumor profiling market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global cancer tumor profiling market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Cancer Type
3.2. Snippet by Technology Type
3.3. Snippet by Biomarker Type
3.4. Snippet by Application
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Cancer
4.1.1.2. Technological Advancements
4.1.1.3. Government Initiatives and Fundings
4.1.2. Restraints
4.1.2.1. High Costs of Procedure
4.1.2.2. Lack of Healthcare Infrastructure
4.1.2.3. Lack of Reimbursement Policies
4.1.2.4. Technical Issues in Collecting Samples
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Cancer Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Lung Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Prostate Cancer
6.4. Breast Cancer
6.5. Colorectal Cancer
6.6. Melanoma Cancer
6.7. Others
7. By Technology Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
7.1.2. Market Attractiveness Index, By Technology Type
7.2. Immunoassays*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Next-Generation Sequencing
7.4. Polymerase Chain Reaction
7.5. In-Situ Hybridization
7.6. Microarray
7.7. Others
8. By Biomarker Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
8.1.2. Market Attractiveness Index, By Biomarker Type
8.2. Genomics Biomarker*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Protein Biomarker
8.4. Others
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Research Applications*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinical Applications
9.4. Diagnostics
9.5. Personalized Medicines
9.6. Others
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic Centers
10.4. Research and Educational Institutions
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.8.1. The U.S.
11.2.8.2. Canada
11.2.8.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. UK
11.3.8.3. France
11.3.8.4. Italy
11.3.8.5. Spain
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.8.1. Brazil
11.4.8.2. Argentina
11.4.8.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8.1. China
11.5.8.2. India
11.5.8.3. Japan
11.5.8.4. South Korea
11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Qiagen N.V *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. NeoGenomics Laboratories
13.3. Genomic Health Inc.
13.4. Caris Life Sciences
13.5. Helomics Corporation
13.6. NanoString Technologies
13.7. Sysmex Corporation
13.8. Ribomed Biotechnologies Inc.
13.9. Roche Diagnostics
13.10. Illumina Inc. (*LIST NOT EXHAUSTIVE)
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Qiagen N.V, 4.	Key Developments, NeoGenomics Laboratories, Genomic Health Inc., Caris Life Sciences, Helomics Corporation, NanoString Technologies, Sysmex Corporation, Ribomed Biotechnologies Inc., Roche Diagnostics

표 목록 (Tables)

List of Tables

Table 1 Global Cancer Tumor Profiling Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Cancer Tumor Profiling Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Cancer Tumor Profiling Market Value, By Technology Type, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Cancer Tumor Profiling Market Value, By Biomarker Type, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Cancer Tumor Profiling Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Cancer Tumor Profiling Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)

Table 7 Global Cancer Tumor Profiling Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 8 Global Cancer Tumor Profiling Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)

Table 9 Global Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 10 Global Cancer Tumor Profiling Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)

Table 11 Global Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)

Table 12 Global Cancer Tumor Profiling Market Value, By Technology Type, 2025, 2029 & 2033 (US$ Billion)

Table 13 Global Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)

Table 14 Global Cancer Tumor Profiling Market Value, By Biomarker Type, 2025, 2029 & 2033 (US$ Billion)

Table 15 Global Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)

Table 16 Global Cancer Tumor Profiling Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 17 Global Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)

Table 18 Global Cancer Tumor Profiling Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)

Table 19 Global Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)

Table 20 Global Cancer Tumor Profiling Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 21 Global Cancer Tumor Profiling Market Value, By Region, 2022-2033 (US$ Billion)

Table 22 North America Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 23 North America Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)

Table 24 North America Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)

Table 25 North America Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)

Table 26 North America Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)

Table 27 North America Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)

Table 28 North America Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)

Table 29 Europe Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 30 Europe Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)

Table 31 Europe Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)

Table 32 Europe Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)

Table 33 Europe Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)

Table 34 Europe Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)

Table 35 Europe Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)

Table 36 Asia-Pacific Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 37 Asia-Pacific Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)

Table 38 Asia-Pacific Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)

Table 39 Asia-Pacific Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)

Table 40 Asia-Pacific Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)

Table 41 Asia-Pacific Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)

Table 42 Asia-Pacific Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)

Table 43 South America Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 44 South America Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)

Table 45 South America Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)

Table 46 South America Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)

Table 47 South America Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)

Table 48 South America Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)

Table 49 South America Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)

Table 50 Middle East and Africa Cancer Tumor Profiling Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 51 Middle East and Africa Cancer Tumor Profiling Market Value, By Cancer Type, 2022-2033 (US$ Billion)

Table 52 Middle East and Africa Cancer Tumor Profiling Market Value, By Technology Type, 2022-2033 (US$ Billion)

Table 53 Middle East and Africa Cancer Tumor Profiling Market Value, By Biomarker Type, 2022-2033 (US$ Billion)

Table 54 Middle East and Africa Cancer Tumor Profiling Market Value, By Application, 2022-2033 (US$ Billion)

Table 55 Middle East and Africa Cancer Tumor Profiling Market Value, By End-User, 2022-2033 (US$ Billion)

Table 56 Middle East and Africa Cancer Tumor Profiling Market Value, By Country, 2022-2033 (US$ Billion)

Table 57 F. Hoffmann-La Roche Ltd.: Overview

Table 58 F. Hoffmann-La Roche Ltd.: Product Portfolio

Table 59 F. Hoffmann-La Roche Ltd.: Key Developments

Table 60 Illumina, Inc.: Overview

Table 61 Illumina, Inc.: Product Portfolio

Table 62 Illumina, Inc.: Key Developments

Table 63 Myriad Genetics, Inc.: Overview

Table 64 Myriad Genetics, Inc.: Product Portfolio

Table 65 Myriad Genetics, Inc.: Key Developments

Table 66 Thermo Fisher Scientific Inc.: Overview

Table 67 Thermo Fisher Scientific Inc.: Product Portfolio

Table 68 Thermo Fisher Scientific Inc.: Key Developments

Table 69 Agilent Technologies, Inc.: Overview

Table 70 Agilent Technologies, Inc.: Product Portfolio

Table 71 Agilent Technologies, Inc.: Key Developments

Table 72 Caris Life Sciences.: Overview

Table 73 Caris Life Sciences.: Product Portfolio

Table 74 Caris Life Sciences.: Key Developments

Table 75 Guardant Health: Overview

Table 76 Guardant Health: Product Portfolio

Table 77 Guardant Health: Key Developments

Table 78 NanoString Technologies (a Bruker Company): Overview

Table 79 NanoString Technologies (a Bruker Company): Product Portfolio

Table 80 NanoString Technologies (a Bruker Company): Key Developments

Table 81 Foundation Medicine, Inc.: Overview

Table 82 Foundation Medicine, Inc.: Product Portfolio

Table 83 Foundation Medicine, Inc.: Key Developments

Table 84 Paragon Genomics, Inc.: Overview

Table 85 Paragon Genomics, Inc.: Product Portfolio

Table 86 Paragon Genomics, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)

Figure 3 Global Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 4 Global Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)

Figure 5 Global Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)

Figure 6 Global Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)

Figure 7 Global Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)

Figure 8 Global Cancer Tumor Profiling Market Share, By Region, 2024 & 2033 (%)

Figure 9 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Product Type, 2023-2033 (%)

Figure 10 Kits and Consumables Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 11 Devices Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 12 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)

Figure 13 Breast Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 14 Lung Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 15 Colorectal Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 16 Prostate Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 17 Leukemias Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 18 Melanoma Cancer Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 19 Others Cancer Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 20 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Technology Type, 2023-2033 (%)

Figure 21 Immunoassay Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 22 Next-Generation Sequencing Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 23 Liquid Biopsy Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 24 Polymerase Chain Reaction Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 25 In-Situ Hybridization Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 26 Microarray Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 27 Others Technology Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 28 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Biomarker Type, 2023-2033 (%)

Figure 29 Genomic Biomarkers Biomarker Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 30 Protein Biomarkers Biomarker Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 31 Others Biomarker Type in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 32 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Application, 2023-2033 (%)

Figure 33 Clinical Applications Application in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 34 Research Applications Application in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 35 Global Cancer Tumor Profiling Market Y-o-Y Growth, By End-User, 2023-2033 (%)

Figure 36 Hospitals End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 37 Diagnostic Centers End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 38 Pharmaceutical and Biotechnology Companies End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 39 Research and Educational Institutions End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 40 Others End-User in Global Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 41 Global Cancer Tumor Profiling Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 42 North America Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 43 North America Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)

Figure 44 North America Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 45 North America Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)

Figure 46 North America Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)

Figure 47 North America Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)

Figure 48 North America Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)

Figure 49 North America Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)

Figure 50 Europe Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 51 Europe Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)

Figure 52 Europe Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 53 Europe Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)

Figure 54 Europe Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)

Figure 55 Europe Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)

Figure 56 Europe Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)

Figure 57 Europe Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)

Figure 58 Asia-Pacific Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 59 Asia-Pacific Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)

Figure 60 Asia-Pacific Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 61 Asia-Pacific Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)

Figure 62 Asia-Pacific Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)

Figure 63 Asia-Pacific Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)

Figure 64 Asia-Pacific Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)

Figure 65 Asia-Pacific Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)

Figure 66 South America Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 67 South America Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)

Figure 68 South America Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 69 South America Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)

Figure 70 South America Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)

Figure 71 South America Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)

Figure 72 South America Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)

Figure 73 South America Cancer Tumor Profiling Market Share, By Country, 2024 & 2033 (%)

Figure 74 Middle East and Africa Cancer Tumor Profiling Market Value, 2022-2033 (US$ Billion)

Figure 75 Middle East and Africa Cancer Tumor Profiling Market Share, By Product Type, 2024 & 2033 (%)

Figure 76 Middle East and Africa Cancer Tumor Profiling Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 77 Middle East and Africa Cancer Tumor Profiling Market Share, By Technology Type, 2024 & 2033 (%)

Figure 78 Middle East and Africa Cancer Tumor Profiling Market Share, By Biomarker Type, 2024 & 2033 (%)

Figure 79 Middle East and Africa Cancer Tumor Profiling Market Share, By Application, 2024 & 2033 (%)

Figure 80 Middle East and Africa Cancer Tumor Profiling Market Share, By End-User, 2024 & 2033 (%)

Figure 81 F. Hoffmann-La Roche Ltd.: Financials

Figure 82 Illumina, Inc.: Financials

Figure 83 Myriad Genetics, Inc.: Financials

Figure 84 Thermo Fisher Scientific Inc.: Financials

Figure 85 Agilent Technologies, Inc.: Financials

Figure 86 Caris Life Sciences.: Financials

Figure 87 Guardant Health: Financials

Figure 88 NanoString Technologies (a Bruker Company): Financials

Figure 89 Foundation Medicine, Inc.: Financials

Figure 90 Paragon Genomics, Inc.: Financials

글로벌 암 종양 프로파일링 시장 – 2024년 – 2031년

Global Cancer Tumor Profiling Market - 2024 - 2031